MetaCap

AstraZeneca PLC (AZN)

NYSE: AZNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

174.35-1.06 (-0.60%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AZN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$270.40B
Dividend yield
1.85% ($3.23)
Ex-dividend date
Feb 19, 2026
52-week range
153.41 – 212.71
Day range
174.06 – 177.47
Volume / Avg
2.02M / 2.93M
Beta
—

52-week range

$153.41$212.71

AZN stock today

Shares of AstraZeneca (AZN) finished lower on Nov 20 at $174.35, a drop of 0.60% or $1.06 per share, versus the S&P 500's 3.70% decline. Shares are 18.0% below their 52-week high of $212.71, set on Feb 18, 2026 and 13.6% above the 52-week low of $153.41, in the middle of the past year's range. AZN is down 5.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 4.2%.

At 24.7x trailing earnings, AstraZeneca trades below the peer-group median of 30.9x. Its forward P/E of 15.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. AstraZeneca pays an annual dividend of $3.23 per share, a 1.85% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About AstraZeneca

Company profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.
Headquarters
Cambridge
Employees
96,100
IPO year
2026

Financial highlights

Full financials

In fiscal 2025, AstraZeneca generated $58.74 billion in revenue, up 8.6% from fiscal 2024, its 7th consecutive year of revenue growth. Net income was $10.22 billion (+45.3% year over year), for a net margin of 17.4% versus a median of 12.0% in the prior 5 years. Gross margin was 81.9% (up from 81.1%) and operating margin 23.4%.

AstraZeneca annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$58.74B$54.07B$45.81B$44.35B$37.42B
Growth+8.63%+18.03%+3.29%+18.53%+40.58%
Net income$10.22B$7.04B$5.96B$3.29B$112.00M
EPS (diluted)$6.54$4.50$3.81$2.11$0.08

Analyst forecast

Forecast

Consensus (12 analysts)

buy

Avg. price target

$209.91+20.40%

  • Strong buy 2
  • Buy 7
  • Hold 2
  • Sell 1
  • Strong sell 0

Target range

Low $158.00High $240.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 30, 2026
EPS actual vs est.
$2.38 vs $2.60
Surprise
-8.46%

Dividends

Dividend history
Annual dividend
$3.23
Last payment
$2.15
Ex-dividend date
Feb 19, 2026

AZN news

All AZN news

AstraZeneca peers

Health Care sector
AZN peer companies
CompanyPrice% ChgMarket capCompare
NVSNovartis AG150.47-0.50%$284.18Bvs AZN
MRKMerck & Company Inc.133.72+0.69%$329.65Bvs AZN
ABTAbbott Laboratories103.00-0.84%$178.39Bvs AZN
NVONovo Nordisk A/S37.82-2.70%$166.69Bvs AZN
PFEPfizer Inc.27.40-0.51%$156.18Bvs AZN
VRTXVertex Pharmaceuticals Incorporated515.02-1.08%$130.58Bvs AZN
BMYBristol-Myers Squibb Company58.80+0.79%$120.19Bvs AZN
SNYSanofi ADS46.52+1.00%$111.70Bvs AZN

Indexes, lists and sector

AstraZeneca stock FAQ

What is AstraZeneca's stock price today?

AZN last traded at $174.35 as of Nov 20, 4:00 PM EST, down 0.60% on the day. Prices are delayed at least 15 minutes.

Does AstraZeneca pay a dividend?

Yes. AstraZeneca pays $3.23 per share annually, a 1.85% yield. The most recent dividend of $2.15 had an ex-dividend date of Feb 19, 2026.

What is AZN's P/E ratio?

AZN trades at a trailing P/E ratio of 24.66 and a forward P/E of 15.41, compared with a median of 30.9 for its closest peers.

Who is AstraZeneca's CEO?

Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. is the chief executive officer of AstraZeneca PLC, which has about 96,100 employees.

Has AZN ever split its stock?

Yes. The most recent AZN stock split was a 1-for-2 split on Feb 2, 2026, one of 3 splits on record.

What is the AZN 52-week high?

The 52-week high for AZN is $212.71 and the 52-week low is $153.41. The stock is currently 18.0% below its high.

Compare AZN